DLBS3233

DRUG5 trials

Sponsors

Dexa Medica Group

Conditions

Insulin ResistanceNew OnsetPolycystic Ovary Syndrome (PCOS)PrediabeticType-2 Diabetes MellitusType-2-diabetes Mellitus

Phase 3

Efficacy and Safety of Add-on Therapy With DLBS3233 in Patients With Type-2 Diabetes Mellitus

CompletedNCT01472614

Dexa Medica GroupType-2 Diabetes Mellitus

Start: 2011-09-30End: 2013-04-30Updated: 2013-05-27

Efficacy and Safety of DLBS3233 in Prediabetic Patients

CompletedNCT01531933

Dexa Medica GroupPrediabetic

Start: 2011-11-30End: 2012-07-31Updated: 2012-08-07

Efficacy and Safety of DLBS3233 in Subjects With New Onset of Type 2 Diabetes Mellitus

CompletedNCT01645332

Dexa Medica GroupNew Onset, Type-2-diabetes Mellitus

Start: 2012-07-31End: 2014-09-30Updated: 2014-10-08

Efficacy and Safety of DLBS3233 in Subjects With Polycystic Ovary Syndrome (PCOS)

CompletedNCT01733459

Dexa Medica GroupPolycystic Ovary Syndrome (PCOS)

Start: 2013-03-31End: 2018-06-30Updated: 2018-07-26

PCOS Treatment Using DLBS3233, Metformin, and Combination of Both

CompletedNCT01999686

Dexa Medica GroupInsulin Resistance, Polycystic Ovary Syndrome (PCOS)

Start: 2014-10-31End: 2019-05-31Updated: 2019-05-28

Related Papers

The Efficacy and Safety of DLBS3233, A Combined Bioactive Fraction of <i>Cinnamomum burmanii</i> and <i>Lagerstroemia</i> speciosa Plants on The Endocrine-Metabolic Profile of Women with Polycystic Ovary Syndrome: A Randomized Clinical Trial.

PubMed2024-07-131 citations

The Effect and Safety Assessment of Metformin and DLBS3233 (A Bioactive Fraction of Lagerstroemia speciosa and Cinnamomum burmannii) on Improving Metabolic Parameters in Women with Polycystic Ovary Syndrome

International Journal of Women s Health2023-07-014 citations